Literature DB >> 6458356

Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells.

E G Adams, S L Crampton, B K Bhuyan.   

Abstract

The effect of 7-con-O-methylnogarol (7-OMEN) on the survival of exponentially growing and plateau-phase Chinese hamster ovary cells was determined in a cloning assay. After 2 hr of exposure, the 50% lethal dose for exponential and plateau-phase cells was 0.3 and 1.5 microgram/ml, respectively. Drug doses for cell progression studies were based upon drug lethality; therefore, higher doses were used for plateau than for exponential populations. The effect of 7-OMEN on cell progression was studied by DNA flow cytometry under the following conditions: (a) during 24 hr of continuous exposure of exponentially growing cells; (b) during recovery of exponential cells after 2 or 7 hr of drug exposure; and (c) during recovery of plateau-phase cells after 2 hr of exposure. Exponential cells exposed continuously for 24 hr progressed normally from M to G1 phase and from G1 to S phase, progression through S phase was slowed, and cells were ultimately blocked in G2 + M. Inhibition of S-phase progression was dose dependent, 0.2 microgram/ml having only slight effect and 1.0 microgram/ml accumulating a large fraction in S phase. Inhibition of S-phase progression correlated with DNA synthesis inhibition. Similar inhibitory effects were observed after pulsed (2- or 7-hr) exposure of exponential cells. 7-OMEN also blocked plateau-phase cells in G2 + M after 2 hr of exposure, but higher doses (3.0 microgram/ml) were required. Simultaneous exposure of exponential cells to Colcemid (which blocks cells in metaphase) and 1.0 microgram 7-OMEN per ml completely inhibited the expected increase in mitotic index, indicating that the G2 + M block observed by DNA flow cytometry was a block in G2 or prophase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458356

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Menogaril: a new anthracycline agent entering clinical trials.

Authors:  J P McGovren; K G Nelson; M Lassus; J C Cradock; J Plowman; J P Christopher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture.

Authors:  B K Bhuyan; G J Badiner; E G Adams; R Chase
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

3.  Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.

Authors:  G J Badiner; R D Hamilton; L H Li; B K Bhuyan
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.

Authors:  B K Bhuyan; K S Smith; E G Adams; T L Wallace; D D Von Hoff; L H Li
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Phase II evaluation of menogaril in patients with advanced hypernephroma.

Authors:  H J Long; M D Hauge; T M Therneau; J C Buckner; S Frytak; R G Hahn
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

7.  Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.

Authors:  H J LONG; H S Wieand; J F Foley; R D Niedringhaus; J A Laurie; R F Morton; R M Goldberg; J A Mailliard; G D Malkasian; J H Edmonson
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

8.  Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation.

Authors:  R A Majack; L V Goodman; V M Dixit
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.